![[hta]DataMine™ — Powered by Pharmalytics Group Technologies](/__l5e/assets-v1/669a0eee-d0b5-44d7-bd1e-5b35cf04668d/hta-datamine-peach.png)
Reimbursement decisions leave patterns. We study them.
[hta]DataMine™ is a proprietary health technology assessment intelligence platform built on the structured analysis of more than 2,500 reimbursement decisions across major agencies and markets.
Coverage includes decisions and assessments from, among others, the National Institute for Health and Care Excellence (NICE), Canada’s Drug Agency (CDA-AMC), the Scottish Medicines Consortium (SMC), the Haute Autorité de Santé (HAS), the Institute for Quality and Efficiency in Health Care (IQWiG), Australia’s Pharmaceutical Benefits Advisory Committee (PBAC), and European Union Joint Clinical Assessments (JCA).
It transforms reimbursement precedent into actionable, decision-relevant insight—showing how agencies have evaluated comparable products, indications, endpoints, comparators, economic evidence, and areas of uncertainty. By benchmarking the clinical, economic, methodological, and contextual factors that shaped previous decisions, the platform helps teams understand not only what agencies decided, but why.
Used across the health technology evidence lifecycle, [hta]DataMine™ supports earlier and more informed decision-making—from evidence planning and generation through submission strategy, technical defence, and post-launch reassessment.
Capabilities
Precedent, translated into strategy.
Precedent mapping
Trace how major health technology assessment agencies have evaluated comparable products, indications, endpoints, comparators, and evidence packages across markets.
Evidence driver benchmarking
Identify the clinical, economic, methodological, and contextual factors that shaped past reimbursement recommendations, restrictions, and pricing expectations.
Submission foresight
Anticipate likely committee questions, evidence challenges, and areas of uncertainty before they emerge during review.
Strategic scenario analysis
Test how alternative evidence, comparator, modelling, and positioning scenarios could affect agency interpretation, reimbursement conditions, and the overall submission strategy.
See how agencies have decided—and why.
Explore how reimbursement precedent can inform your evidence strategy, pressure-test your submission, and strengthen decision-making across the product lifecycle.